# Vuzix

Type: Company (VUZI)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/vuzix
Canonical HTML page: https://getfinancebrief.com/entity/vuzix

## Timeline

- **2026-03-12**: Q4 2025 Earnings — Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
- **2026-03-09**: FDA NDA Acceptance — FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
- **2026**: PDUFA Goal Date — Expected timeframe for the FDA's final decision on Lorundrostat commercialization.

## Recent coverage (1 stories)

### Mineralys and Vuzix Q4 Earnings: Biotech Milestones vs. AR Scaling
2026-03-12 23:34:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Full story: https://getfinancebrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.